Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, with a primary focus on neuromuscular diseases.

Voir plus

March 30, 2020

Biophytis Receives Approval from the Belgian Regulatory Agency to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with DMD. Read the Press Release

March 24, 2020

Biophytis Completes Recruitment of SARA-INT Phase 2b Study, Evaluating the Efficacy of Sarconeos (BIO101) in the Treatment of Sarcopenia. Read the Press Release

March 17, 2020

Biophytis Reports 2019 Full Year Results and Provides Operational Update. Read the Press Release

Our science

Our therapeutic approach is aimed at targeting and activating key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative and metabolic stresses that lead to age-related diseases.

See more


Our lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD. Our second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry AMD and Stargardt disease.

See more



Biophytis has been listed on the market Euronext Growth Paris
since July 13, 2015.

ISIN : FR0012816825
Ticker: ALBPS
Type of listing : continuous
Number of outstanding shares: 39,707,325 (as of April 1st, 2020)
Eligible for PEA and PEA-PME equity saving plans

Click here for live stock price

See more